Back
Sep 28
Scientific
SS 03 - GU 1: Advances in Localized Prostate Cancer
MODERATOR(S)
Neil Desai, MD - University of Texas Southwestern Medical Center
Emily Weg, MD - Weill Cornell Medicine
Credits
| AMA PRA Category 1 Credits: | 1.25 |
Presentations
-
02:30pm - 03:45pm PT
GU 1: Advances in Localized Prostate Cancer
Speaker: Emily Weg, MD - Weill Cornell Medicine, New York -
02:30pm - 03:45pm PT
GU 1: Advances in Localized Prostate Cancer
Speaker: Neil Desai, MD - University of Texas Southwestern Medical Center, Dallas -
03:30pm - 03:35pm PT
5-Year Results of a Prospective, Non-Randomized Controlled Study: Comparison of the Efficacy and Safety of ADT + Docetaxel vs. ADT + Novel Hormone Therapy in High Gleason Score Non-Metastatic Prostate
Speaker: Mingwei Ma, MD - Peking University First Hospital, Beijing -
02:30pm - 02:40pm PT
Primary results from NRG-GU005: A Phase III Trial of SBRT vs. Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Speaker: Rodney Ellis, - University of South Florida/Tampa GeneralHospital, Tampa -
02:30pm - 02:40pm PT
Phase 3, Randomized, Placebo Controlled Clinical Trial of CAN-2409+Prodrug in Combination with Standard of Care External Beam Radiation (EBRT) for Newly Diagnosed Localized Prostate Cancer
Speaker: Glen Gejerman, MD, MBA - Hackensack University Medical Center, Hackensack -
02:40pm - 02:50pm PT
Stereotactic Radiotherapy in 3 Fractions for Localized Prostate Cancer
Speaker: Giuseppe Sanguineti, MD, Mr - Regina Elena National Cancer Institute, Rome -
02:50pm - 03:00pm PT
Two-Year Clinical Outcomes Following Ablative Radiotherapy for Unfavorable Prostate Tumors (ABRUPT)
Speaker: Chiara Chissotti, MD - University of Milan Bicocca - School of Medicine and Surgery, Milan -
03:00pm - 03:10pm PT
Outcomes Following Radiation Therapy and Radical Prostatectomy in Patients with High Risk Prostate Cancer in a Similar Access System
Speaker: Abhishek Kumar, MD, MAS - Duke Cancer Institute, Durham -
03:10pm - 03:20pm PT
-
03:20pm - 03:30pm PT